About us | Neuronano®

About us

Neuronano is an innovative Swedish company that develops products for safer and more effective treatment of Parkinson’s disease and other illnesses. Neuronano has developed and patented a new generation of implantable electrodes for Deep Brain Stimulation (DBS) treatment. The solution comprises thinner, more flexible electrodes that are more biocompatible than those used in today’s DBS treatments. This will most likely result in better patient safety, fewer side effects and improved quality of life.

Background

Neuronano AB was founded in 2006 by Prof. Jens Schouenborg and Investor Per-Anders Johansson with the vision to create a patent portfolio of bio-friendly, implantable electrode technology as well as commercial products that can improve life for people, primarily with Parkinson’s disease.

Future

The future is very promising both for Neuronano as a company and for patients who currently suffer from or are limited by disease, and who may be helped by the technology tomorrow.

History

The Neuronano Research Center (NRC) led by Dr Jens Schouenborg, PhD is an interdisciplinary Research and Innovation center focusing on developing a new generation of neural interfaces for communication with the nervous system in basic research and clinical applications.

Mission & Vision

Our mission is to invent, patent, develop and commercialise a new generation of innovative electrodes for implantation in the brain and spinal cord. Our vision is to develop groundbreaking “Neuro Modulation” technologies.

Partners

See all of our partners.

NRC-faculty of medicine

The Neuronano Research Center (NRC) is a cross-disciplinary research and innovation center at Lund University, headed by professor Jens Schouenborg.